A Phase I/IIa, Open Label, Dose-escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy

Trial Profile

A Phase I/IIa, Open Label, Dose-escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Vinorelbine (Primary)
  • Indications Lymphoma; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Taiwan Liposome Company
  • Most Recent Events

    • 11 Jul 2017 Status changed from not yet recruiting to recruiting according to a Taiwan Liposome Company media release.
    • 19 Oct 2016 According to TLC media release, US FDA granted Orphan Drug Designation to TLC178 for the Treatment of Cutaneous T-cell Lymphoma and approval for this phase I/II study.
    • 06 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top